| | |
每
分享 |
| |
共計
|
| ||||||
首次公開發行價格 | | | | $ | 9.50 | | | | | $ | 22,800,000 | | |
承銷折扣及佣金(1) | | | | $ | 0.665 | | | | | $ | 1,596,000 | | |
在支出前,我們得到的收益 | | | | $ | 8.835 | | | | | $ | 21,204,000 | | |
| | |
頁
|
||
招股章程摘要
|
| | | | 1 |
財務數據摘要
|
| | | | 9 |
危險因素
|
| | | | 12 |
關於前瞻性聲明的特別説明
|
| | | | 30 |
收益的使用
|
| | | | 32 |
股利政策
|
| | | | 33 |
資本化
|
| | | | 34 |
稀釋
|
| | | | 36 |
精選財務數據和Pro Forma財務數據
|
| | | | 38 |
管理層對財務狀況及經營成果的探討與分析
|
| | | | 41 |
商業
|
| | | | 50 |
管理
|
| | | | 79 |
執行董事薪酬
|
| | | | 86 |
某些關係和關聯方交易
|
| | | | 92 |
主要股東
|
| | | | 94 |
股本描述
|
| | | | 96 |
有資格出售的股票
|
| | | | 101 |
美國聯邦所得税對非美國持有者的影響
|
| | | | 103 |
承保
|
| | | | 108 |
法律事項
|
| | | | 113 |
專家們
|
| | | | 113 |
在那裏你可以找到更多的信息
|
| | | | 113 |
財務報表索引
|
| | | | F-1 |
| | 靶向治療 (FDA標籤日期) |
| |
癌症類型
|
| |
生物標誌物
|
| |
目標
響應率(1) |
| | |||
| | 赫賽汀® (04/17) | | |
豐胸
|
| |
HER 2
|
| | |
|
16%
|
| | |
| | 佩耶塔® (03/16) | | |
豐胸
|
| |
HER 2
|
| | |
|
11%
|
| | |
| | 吉洛蒂夫® (07/13) | | |
肺
|
| |
EGFR突變
|
| | |
|
31%
|
| | |
| | 沃芬特® (05/17) | | |
腎
|
| |
沒有
|
| | |
|
27%
|
| | |
| | Erbitux® (10/16) | | |
結腸
|
| |
EGFR/K-RAS WT
|
| | |
|
18%
|
| | |
| | |
終結年數
十二月三十一日, |
| |
六個月結束
六月三十日, |
| ||||||||||||||||||
| | |
2015
|
| |
2016
|
| |
2016
|
| |
2017
|
| ||||||||||||
| | | | | | | | | | | | | | |
(未經審計)
|
| |||||||||
業務報表數據: | | | | | | | | | | | | | | | | | | | | | | | | | |
業務費用: | | | | | | | | | | | | | | | | | | | | | | | | | |
研發
|
| | | $ | 2,011,719 | | | | | $ | 3,064,762 | | | | | $ | 1,412,056 | | | | | $ | 2,212,629 | | |
一般和行政
|
| | | | 250,091 | | | | | | 263,664 | | | | | | 131,417 | | | | | | 386,963 | | |
業務費用共計 | | | | | 2,261,810 | | | | | | 3,328,426 | | | | | | 1,543,473 | | | | | | 2,599,592 | | |
業務損失 | | | | | (2,261,810) | | | | | | (3,328,426) | | | | | | (1,543,473) | | | | | | (2,599,592) | | |
其他收入(費用): | | | | | | | | | | | | | | | | | | | | | | | | | |
利息費用
|
| | | | — | | | | | | — | | | | | | — | | | | | | (186,686) | | |
利息收入
|
| | | | 268 | | | | | | 18,018 | | | | | | 4,019 | | | | | | 22,712 | | |
其他收入(費用)共計 | | | | | 268 | | | | | | 18,018 | | | | | | 4,019 | | | | | | (163,974) | | |
淨損失 | | | | $ | (2,261,542) | | | | | $ | (3,310,408) | | | | | $ | (1,539,454) | | | | | $ | (2,763,566) | | |
普通股股東每股淨虧損-基本虧損和稀釋損失(1)
|
| | | $ | (0.39) | | | | | $ | (0.52) | | | | | $ | (0.25) | | | | | $ | (0.43) | | |
加權平均(WA)普通股發行,用於計算普通股的單位淨虧損.基礎和稀釋(1)
|
| | | | 5,843,317 | | | | | | 6,313,089 | | | | | | 6,181,660 | | | | | | 6,440,139 | | |
專業表格調整:(2)(3) | | | | | | | | | | | | | | | | | | | | | | | | | |
可兑換票據利息的初步調整(4)
|
| | | | | | | | | | — | | | | | | — | | | | | | 186,686 | | |
形式上的淨損失(5) | | | | | | | | | | $ | (3,310,408) | | | | | $ | (1,539,454) | | | | | $ | (2,576,880) | | |
WA普通股流通股(未經審計):
|
| | | | | | | | | | | | | | | | | | | | | | | | |
可兑換票據轉換導致的形式成立的WA普通股(6)
|
| | | | | | | | | | — | | | | | | — | | | | | | 277,451 | | |
| | |
終結年數
十二月三十一日, |
| |
六個月結束
六月三十日, |
| |||||||||||||||
| | |
2015
|
| |
2016
|
| |
2016
|
| |
2017
|
| |||||||||
| | | | | | | | | | | |
(未經審計)
|
| |||||||||
形式上的WA普通股已發行
用於計算每股淨虧損 可歸因於共同股東-基本 稀釋(7) |
| |
|
| | | | 6,313,089 | | | | | | 6,181,660 | | | | | | 6,717,590 | | |
普通股股東每股淨虧損-基本虧損和稀釋損失
|
| | | | | | $ | (0.52) | | | | | $ | (0.25) | | | | | $ | (0.38) | | |
|
| | |
截至
十二月三十一日, |
| |
截至
2017.6月30日 |
| ||||||||||||||||||||||||
| | |
2015
|
| |
2016
|
| ||||||||||||||||||||||||
| | |
實際
|
| |
實際
|
| |
實際
|
| |
親Forma(2)
|
| |
親Forma(3)
作為調整 |
| |||||||||||||||
| | | | | | | | | | | | | | |
(未經審計)
|
| |
(未經審計)
|
| |
(未經審計)
|
| |||||||||
資產負債表數據: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
現金和現金等價物 | | | | $ | 5,067,240 | | | | | $ | 5,856,348 | | | | | $ | 10,908,068 | | | | | $ | 10,908,068 | | | | | $ | 31,037,132 | | |
總資產 | | | | | 5,300,025 | | | | | | 6,056,977 | | | | | | 11,686,950 | | | | | | 11,686,950 | | | | | | 31,514,284 | | |
流動負債總額 | | | | | 283,604 | | | | | | 445,359 | | | | | | 776,954 | | | | | | 776,954 | | | | | | 500,288 | | |
可兑換票據 | | | | | — | | | | | | — | | | | | | 6,575,413 | | | | | | — | | | | | | — | | |
股東權益總額(1) | | | | | 5,016,421 | | | | | | 5,611,618 | | | | | | 4,334,583 | | | | | | 10,909,996 | | | | | $ | 31,013,996 | | |
| | |
截至2017
|
| ||||||||||||||||||
| | |
實際
|
| |
親Forma
注 轉換 |
| |
親Forma
作為調整 |
| | |||||||||||
| | |
(除股票和每股數據外,以千計;未經審計)
|
| | |||||||||||||||||
現金、現金等價物和有價證券(不包括限制性現金)
|
| | | $ | 10,908 | | | | | $ | 10,908 | | | | | $ | 31,037 | | | | ||
可兑換票據(1) | | | | | 6,575 | | | | | | — | | | | | | — | | | | ||
股東權益 | | | | | | | | | | | | | | | | | | | | | ||
普通股,面值0.001美元(2)
|
| | | | 6 | | | | | | 7 | | | | | | 10 | | | | ||
額外已付資本(1)
|
| | | | 15,424 | | | | | | 21,998 | | | | | | 42,100 | | | | ||
累積赤字
|
| | | | (11,095) | | | | | | (11,095) | | | | | | (11,095) | | | | ||
股東權益總額
|
| | | | 4,335 | | | | | | 10,910 | | | | | | 31,014 | | | | ||
總資本化 | | | | $ | 10,910 | | | | | $ | 10,910 | | | | | $ | 31,014 | | | |
| 首次公開發行每股價格 | | | | | | | | | | $ | 9.50 | | |
|
歷史有形賬面價值,截至6月30日,2017
LLC轉換的實現 |
| | | $ | 0.63 | | | | |||||
|
有形帳面淨值初步增加
無擔保可兑換本票的轉換 |
| | | $ | 0.82 | | | | | | | | |
|
截至2017年度6月30日每股有形帳面淨值
|
| | | $ | 1.45 | | | | | | | | |
|
有形帳面淨值初步增加
新投資者 |
| | | $ | 1.74 | | | | | | | | |
|
經調整後每股有形賬面價值調整後的形式
|
| | | | | | | | | $ | 3.19 | | |
|
向購買普通股的新投資者每股稀釋
供品 |
| | | | | | | | | $ | 6.31 | | |
|
| | |
購買的股份
|
| |
總審議
|
| |
平均
價格 每股 |
| |||||||||||||||||||||
| | |
數
|
| |
百分比
|
| |
金額
|
| |
百分比
|
| ||||||||||||||||||
現有股東 | | | | | 7,322,050 | | | | | | 75.3% | | | | | $ | 23,081,433 | | | | | | 50.3% | | | | | $ | 3.15 | | |
新投資者 | | | | | 2,400,000 | | | | | | 24.7 | | | | | | 22,800,000 | | | | | | 49.7 | | | | | | 9.50 | | |
共計
|
| | | | 9,722,050 | | | | | | 100% | | | | | $ | 45,881,433 | | | | | | 100% | | | | | $ | 4.72 | | |
| | |
終結年數
十二月三十一日, |
| |
六個月結束
六月三十日, |
| ||||||||||||||||||
| | |
2015
|
| |
2016
|
| |
2016
|
| |
2017
|
| ||||||||||||
| | | | | | | | | | | | | | |
(未經審計)
|
| |||||||||
業務報表數據: | | | | | | | | | | | | | | | | | | | | | | | | | |
業務費用: | | | | | | | | | | | | | | | | | | | | | | | | | |
研發
|
| | | $ | 2,011,719 | | | | | $ | 3,064,762 | | | | | $ | 1,412,056 | | | | | $ | 2,212,629 | | |
一般和行政
|
| | | | 250,091 | | | | | | 263,664 | | | | | | 131,417 | | | | | | 386,963 | | |
業務費用共計 | | | | | 2,261,810 | | | | | | 3,328,426 | | | | | | 1,543,473 | | | | | | 2,599,592 | | |
業務損失 | | | | | (2,261,810) | | | | | | (3,328,426) | | | | | | (1,543,473) | | | | | | (2,599,592) | | |
其他收入(費用): | | | | | | | | | | | | | | | | | | | | | | | | | |
利息費用
|
| | | | — | | | | | | — | | | | | | — | | | | | | (186,686) | | |
利息收入
|
| | | | 268 | | | | | | 18,018 | | | | | | 4,019 | | | | | | 22,712 | | |
其他收入(費用)共計 | | | | | 268 | | | | | | 18,018 | | | | | | 4,019 | | | | | | (163,974) | | |
淨損失 | | | | $ | (2,261,542) | | | | | $ | (3,310,408) | | | | | $ | (1,539,454) | | | | | $ | (2,763,566) | | |
普通股股東每股淨虧損-基本虧損和稀釋損失(1)
|
| | | $ | (0.39) | | | | | $ | (0.52) | | | | | $ | (0.25) | | | | | $ | (0.43) | | |
加權平均(WA)普通股發行,用於計算普通股的單位淨虧損.基礎和稀釋(1)
|
| | | | 5,843,317 | | | | | | 6,313,089 | | | | | | 6,181,660 | | | | | | 6,440,139 | | |
專業表格調整:(2)(3) | | | | | | ||||||||||||||||||||
可兑換票據利息的初步調整(4)
|
| | | | | | | | | | — | | | | | | — | | | | | | 186,686 | | |
形式上的淨損失(5) | | | | | | | | | | $ | (3,310,408) | | | | | $ | (1,539,454) | | | | | $ | (2,576,880) | | |
WA普通股流通股(未經審計):
|
| | | | | | | | | | | | | | | | | | | | | | | | |
可兑換票據轉換導致的形式成立的WA普通股(6)
|
| | | | | | | | | | — | | | | | | — | | | | | | 277,451 | | |
形式上的WA普通股已發行
用於計算每股淨虧損 可歸因於共同股東-基本 稀釋(7) |
| | | | | | | | | | 6,313,089 | | | | | | 6,181,660 | | | | | | 6,717,590 | | |
普通股股東每股淨虧損-基本虧損和稀釋損失
|
| | | | | | | | | $ | (0.52) | | | | | $ | (0.25) | | | | | $ | (0.38) | | |
|
| | |
截至
十二月三十一日, |
| |
截至
2017.6月30日 |
| ||||||||||||||||||||||||
| | |
2015
|
| |
2016
|
| ||||||||||||||||||||||||
| | |
實際
|
| |
實際
|
| |
實際
|
| |
親Forma(2)
|
| |
親Forma(3)
作為調整 |
| |||||||||||||||
| | | | | | | | | | | | | | |
(未經審計)
|
| |
(未經審計)
|
| |
(未經審計)
|
| |||||||||
資產負債表數據: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
現金和現金等價物 | | | | $ | 5,067,240 | | | | | $ | 5,856,348 | | | | | $ | 10,908,068 | | | | | $ | 10,908,068 | | | | | $ | 31,037,132 | | |
總資產 | | | | | 5,300,025 | | | | | | 6,056,977 | | | | | | 11,686,950 | | | | | | 11,686,950 | | | | | | 31,514,284 | | |
流動負債總額 | | | | | 283,604 | | | | | | 445,359 | | | | | | 776,954 | | | | | | 776,954 | | | | | | 500,288 | | |
可兑換票據 | | | | | — | | | | | | — | | | | | | 6,575,413 | | | | | | — | | | | | | — | | |
股東權益總額(1) | | | | | 5,016,421 | | | | | | 5,611,618 | | | | | | 4,334,583 | | | | | | 10,909,996 | | | | | $ | 31,013,996 | | |
| | |
終結年數
十二月三十一日, |
| |
增加
(減少) |
| ||||||||||||||||||
| | |
2015
|
| |
2016
|
| |
$
|
| |
%
|
| ||||||||||||
業務費用: | | | | | | | | | | | | | | | | | | | | | | | | | |
研發
|
| | | $ | 2,011,719 | | | | | $ | 3,064,762 | | | | | $ | 1,053,043 | | | | | | 52% | | |
一般和行政
|
| | | | 250,091 | | | | | | 263,664 | | | | | | 13,573 | | | | | | 5% | | |
業務費用共計 | | | | | 2,261,810 | | | | | | 3,328,426 | | | | | | 1,066,616 | | | | | | 47% | | |
業務損失 | | | | | (2,261,810) | | | | | | (3,328,426) | | | | | | (1,066,616) | | | | | | 47% | | |
利息收入 | | | | | 268 | | | | | | 18,018 | | | | | | 17,750 | | | | | | 6,623% | | |
淨損失 | | | | $ | (2,261,542) | | | | | $ | (3,310,408) | | | | | $ | (1,048,866) | | | | | | 46% | | |
|
| | |
六個月結束
六月三十日, |
| |
增加
(減少) |
| ||||||||||||||||||
| | |
2016
|
| |
2017
|
| |
$
|
| |
%
|
| ||||||||||||
| | |
(未經審計)
|
| | | |||||||||||||||||||
業務費用: | | | | | | | | | | | | | | | | | | | | | | | | | |
研發
|
| | | $ | 1,412,056 | | | | | $ | 2,212,629 | | | | | $ | 800,573 | | | | | | 57% | | |
一般和行政
|
| | | | 131,417 | | | | | | 386,963 | | | | | | 255,546 | | | | | | 194% | | |
業務費用共計 | | | | | 1,543,473 | | | | | | 2,599,592 | | | | | | 1,056,119 | | | | | | 68% | | |
業務損失 | | | | | (1,543,473) | | | | | | (2,599,592) | | | | | | (1,056,119) | | | | | | 68% | | |
其他收入(費用): | | | | | | | | | | | | | | | | | | | | | | | | | |
利息費用
|
| | | | — | | | | | | (186,686) | | | | | | (186,686) | | | | | | n/a | | |
利息收入
|
| | | | 4,019 | | | | | | 22,712 | | | | | | 18,693 | | | | | | 465% | | |
其他收入(費用)共計 | | | | | 4,019 | | | | | | (163,974) | | | | | | (167,993) | | | | | | 4,180% | | |
淨損失 | | | | $ | (1,539,454) | | | | | $ | (2,763,566) | | | | | $ | (1,224,112) | | | | | | 80% | | |
|
| | |
終結年數
十二月三十一日, |
| |
六個月結束
六月三十日, |
| ||||||||||||||||||
| | |
2015
|
| |
2016
|
| |
2016
|
| |
2017
|
| ||||||||||||
| | | | | | | | | | | | | | |
(未經審計)
|
| |||||||||
現金淨額:(使用): | | | | | | | | | | | | | | | | | | | | | | | | | |
經營活動
|
| | | $ | (1,978,780) | | | | | $ | (2,888,288) | | | | | $ | (1,402,893) | | | | | $ | (2,209,733) | | |
投資活動
|
| | | | (78,982) | | | | | | (40,903) | | | | | | (29,863) | | | | | | (165,851) | | |
籌資活動
|
| | | | 4,802,394 | | | | | | 3,718,299 | | | | | | 3,718,300 | | | | | | 7,427,304 | | |
現金及現金等價物淨增加情況 | | | | $ | 2,744,632 | | | | | $ | 789,108 | | | | | $ | 2,285,544 | | | | | $ | 5,051,720 | | |
|
| | |
終結年數
十二月三十一日, |
| |
六個月結束
六月三十日, |
| ||||||||||||||||||
| | |
2015
|
| |
2016
|
| |
2016
|
| |
2017
|
| ||||||||||||
預期任期(以年份為單位) | | | | | 6.25 – 10.00 | | | | | | 6.25 – 10.00 | | | | | | 6.25 – 10.00 | | | | | | 6.25 – 10.00 | | |
波動率 | | | | | 72% | | | | | | 75% | | | | | | 72% | | | | | | 75% | | |
無風險利率 | | | | | 1.98% | | | | | | 2.00% | | | | | | 2.00% | | | | | | 2.00% | | |
預期股利收益率 | | | | | 0% | | | | | | 0% | | | | | | 0% | | | | | | 0% | | |
| | |
終結年數
十二月三十一日, |
| |
六個月結束
六月三十日, |
| ||||||||||||||||||
| | |
2015
|
| |
2016
|
| |
2016
|
| |
2017
|
| ||||||||||||
研發 | | | | $ | 56,507 | | | | | $ | 187,307 | | | | | $ | 36,301 | | | | | $ | 294,189 | | |
一般和行政 | | | | | — | | | | | | — | | | | | | — | | | | | | 128,627 | | |
共計 | | | | $ | 56,507 | | | | | $ | 187,307 | | | | | $ | 36,301 | | | | | $ | 422,816 | | |
|
發放日期
|
| |
數目
股份 普通股 標的股票 授予期權 |
| |
運動價格
每股 |
| |
公允價值
每股 授予日期 |
| |||||||||
第一季,2015 | | | | | 37,500 | | | | | $ | 3.60 | | | | | $ | 3.60 | | |
第2季,2015 | | | | | 4,525 | | | | | $ | 3.60 | | | | | $ | 3.60 | | |
第3季,2015 | | | | | 4,500 | | | | | $ | 3.60 | | | | | $ | 3.60 | | |
第4季,2015 | | | | | 5,250 | | | | | $ | 3.60 | | | | | $ | 3.60 | | |
第4季,2015 | | | | | 500 | | | | | $ | 7.60 | | | | | $ | 7.60 | | |
第2季,2016 | | | | | 169,750 | | | | | $ | 7.60 | | | | | $ | 7.60 | | |
第3季,2016 | | | | | 6,063 | | | | | $ | 7.60 | | | | | $ | 7.60 | | |
第4季,2016 | | | | | 14,250 | | | | | $ | 7.60 | | | | | $ | 7.60 | | |
第一季,2017 | | | | | 3,750 | | | | | $ | 7.60 | | | | | $ | 7.60 | | |
第2季,2017 | | | | | 144,400 | | | | | $ | 8.40 | | | | | $ | 7.60 | | |
| | 潛在CDX程序數 | | |
50
|
| |
| | 每個CDX項目的臨牀試驗試驗次數 | | |
3,000
|
| |
| | 每個測試價格 | | |
$4,000
|
| |
| | 潛在臨牀試驗收入總額(A) | | |
$600,000,000
|
| |
| | 每個項目的里程碑付款 | | |
$20,000,000
|
| |
| | 潛在里程碑付款總額(B) | | |
$1,000,000,000
|
| |
| | 潛在收入總額---所有方案(A+B) | | |
$1,600,000,000
|
| |
| | 平均CDX計劃收入 | | |
$32,000,000
|
| |
| |
疾病類型
|
| |
測試合格
病人 |
| |
年度收入
|
| | ||||||
| |
乳房(HER 2-)
|
| | | | 278,230 | | | | | $ | 1,112,918,400 | | | |
| |
非小細胞肺癌
|
| | | | 263,612 | | | | | $ | 1,054,446,000 | | | |
| |
卵巢
|
| | | | 29,051 | | | | | $ | 116,204,800 | | | |
| |
結腸
|
| | | | 146,000 | | | | | $ | 580,983,800 | | | |
| |
膀胱
|
| | | | 68,072 | | | | | $ | 272,247,800 | | | |
| |
腎
|
| | | | 57,084 | | | | | $ | 225,280,800 | | | |
| |
白血病
|
| | | | 40,294 | | | | | $ | 161,175,200 | | | |
| | | | | | | 880,814 | | | | | $ | 3,523,256,800 | | | |
| |
靶向治療
|
| |
類型
癌 |
| |
生物標誌物
|
| |
目標
響應率(1) |
| | |||
| |
赫賽汀® (04/17)
|
| |
豐胸
|
| |
HER 2
|
| | |
|
16%
|
| | |
| |
佩耶塔® (03/16)
|
| |
豐胸
|
| |
HER 2
|
| | |
|
11%
|
| | |
| |
吉洛蒂夫® (07/13)
|
| |
肺
|
| |
EGFR突變
|
| | |
|
31%
|
| | |
| |
沃芬特® (05/17)
|
| |
腎
|
| |
沒有
|
| | |
|
27%
|
| | |
| |
Erbitux® (10/16)
|
| |
結腸
|
| |
EGFR/K-RAS WT
|
| | |
|
18%
|
| | |
| |
參數
|
| |
臨牀試驗
所需 |
| |
優先狀態
|
| |
凱爾特
|
| |
凱爾特
進步 |
| |
| |
樣本
組成 |
| |
細胞羣體
測試必須反映 起始腫瘤 構圖 |
| |
多通道
培養過程 要求使用 輻照 非腫瘤 細胞 |
| |
只有病人腫瘤
細胞 導出樣本 |
| |
細胞測試鏡
非均一性 病人腫瘤 組織 |
| |
| |
培養
期間 |
| |
|
| |
2個−6個月(1)
|
| |
|
| |
取得的結果
臨牀相關 窗 |
| |
| |
產量
|
| |
>90%
|
| |
(1)
|
| |
95%
|
| |
可靠性超過
臨牀試驗 所需 |
| |
| |
通路
|
| | |
腫瘤部位
|
| |
| |
HER 2
|
| | |
當前研發
豐胸 肺 膀胱 腎 卵巢 未來研發 結直腸 骨髓 頭頸 食道 胃 |
| |
| |
路徑1
|
| | ||||
| |
路徑2
|
| | ||||
| |
路徑3
|
| | ||||
| |
路徑4
|
| | ||||
| |
路徑5
|
| | ||||
| |
路徑6
|
| | ||||
| |
路徑7
|
| | ||||
| |
路徑8
|
| |
| | | | |
診斷
|
| |
CELx HER 2測試
|
| | ||||||||||||||||||||||||||||||
| | | | |
小學
|
| |
經常性
|
| |
目標人口
|
| | |||||||||||||||||||||||||||
| |
BC型
|
| |
%
|
| |
#
|
| |
%
|
| |
#
|
| |
%
|
| |
#
|
| | ||||||||||||||||||
| |
HER 2-,ER+
|
| | | | 67% | | | | | | 165,312 | | | | | | 67% | | | | | | 100,800 | | | | | | 80% | | | | | | 212,890 | | | |
| |
HER 2-,ER-
|
| | | | 17% | | | | | | 40,590 | | | | | | 17% | | | | | | 24,750 | | | | | | 100% | | | | | | 65,340 | | | |
| | | | | | | 84% | | | | | | 205,902 | | | | | | 84% | | | | | | 125,550 | | | | | | 84% | | | | | | 278,230 | | | |
|
CELx HSF測試包括以下步驟:
1.
HER 1和HER 3的HER 2雜二聚所驅動的信號傳遞措施:
a.
用HER 3配體(NRG 1)和HER 1配體(EGF)激活PI3K和MAPK;
b.
確認信號是HER 2驅動的,使用HER 2二聚體阻斷劑;
2.
量化HER 2信號轉導抗HER 2藥物的數量;
3.
報告HER 2信號在14天內正常或異常。
|
| |
|
|
| | | | |
細胞株
|
| | |||
| |
參數
|
| |
HCC 1954
|
| |
BT 483
|
| |
| |
HER 2受體表達
|
| |
HER 2+
(3+) |
| |
HER 2-
(0) |
| |
| |
HER 2信令狀態(CELx)
|
| |
正常
|
| |
異常
|
| |
| |
雷帕替尼抑制(異種移植物)
|
| |
13%
(p = 0.34) |
| |
49%
(p = 0.01) |
| |
| |
HER 2單抗
|
| |
HER 2+
細胞株 |
| |
HER 2-(HER 2)S+)
初選 |
| |
| |
pertuzumab
|
| |
62%
|
| |
73%
|
| |
| |
trastuzumab
|
| |
19%
|
| |
44%
|
| |
| |
T+P
|
| |
87%
|
| |
81%
|
| |
| |
HER 2藥物
|
| |
行動機制
|
| |
細胞株
(HER 2+) |
| |
初選
(HER 2-/) HER 2S+) |
| |
| |
pertuzumab
|
| | HER 2二聚抑制劑 | | |
46%
|
| |
78%
|
| |
| |
雷帕替尼b
|
| | 可逆對偶RTKI | | |
15%
|
| |
69%
|
| |
| |
阿法提尼b
|
| |
不可逆共價對偶RTKI
|
| |
47%
|
| |
93%
|
| |
| |
奈拉替尼
|
| |
不可逆共價對偶RTKI
|
| |
95%
|
| |
100%
|
| |
| |
性能特性
|
| |
結果
|
| |
| | 分析精度(定性) | | | | | |
| | 分析靈敏度(95%CI) | | |
95.8%–100% (88/88)
|
| |
| | 分析特異性(95%CI) | | |
95.8%–100% (88/88)
|
| |
| | 檢出限 | | | | | |
| | 空白極限 | | |
0.0020細胞附着單元
|
| |
| | 檢測極限 | | |
0.0099細胞附着單元
|
| |
| | 切斷特性 | | |
250個信令單元
|
| |
| | 結轉 | | |
0%
|
| |
| |
目標
|
| | | 新佐劑HER 2藥物治療早期HER 2-/HER 2的療效評價S+ 乳腺癌患者 | | |
| | 網站/贊助商 | | | |
與nsa bp和Genentech合作的多中心
|
| |
| | 學科 | | | |
55 HER2-早期乳腺癌(26 ER+/29 er-)
|
| |
| | 終點 | | | |
病理完全反應(ypT0/Tis ypN0)
|
| |
| |
調查
(單)臂 |
| | | n=55(HER 2)S+) ac-T+Trastuzumab+Pertuzumab |
| |
| | | | | |
使用的細胞樣本類型:
|
| | ||||
| | | | | |
死亡腫瘤細胞
(固定,溶解) |
| | |
活腫瘤細胞
|
| |
| |
進行分析的類型
|
| | |
單點時間突變
狀態或蛋白質量,或 激活狀態 |
| | |
量化信號通路
24小時活動 |
| |
| |
與疾病驅動者的關係
|
| | |
相關
|
| | |
直接原因
|
| |
| |
疾病驅動程序評估
|
| | |
不知道。只有一組或一小部分
單元的組成部分是 評價 |
| | |
是的。整體的活動
信號通路評估 |
| |
| |
藥物功能評價
|
| | |
不知道。無法評估藥物功能
死細胞 |
| | |
是的。藥物對信號轉導的影響
患者細胞的通路活性 數量化 |
| |
| |
公司
|
| | |
基礎醫學,Caris生命
科學,新基因組學, LabCorp,Quest,NanoString, 範例,生物概念,外顯子 診斷學,健康衞士, 羅氏診斷學家 無數,基因組健康 |
| | |
凱爾特
|
| |
| |
公司
|
| |
產品
|
| |
清單價格
|
| |
| |
基因組健康
|
| |
腫瘤型乳腺癌復發試驗
|
| |
$4,620(1)
|
| |
| |
基礎醫學
|
| |
建立一種固體腫瘤遺傳圖譜檢測方法
|
| |
$5,800(2)
|
| |
| |
維拉西特
|
| |
甲狀腺癌診斷試驗
|
| |
$3,200(3)
|
| |
| |
主題事項
|
| |
專利/申請#
|
| |
地位
|
| |
優先權
日期 |
| |
過期
|
| |
| |
細胞信號分析治療癌症患者的方法
|
| |
9,404,915美元
|
| |
美國批准;歐洲和日本待定
|
| |
6/12/2012
|
| |
2033
|
| |
| |
細胞信號分析治療癌症患者的方法
|
| |
15/192,280美元
|
| |
美國待決
|
| |
6/12/2012
|
| |
2033
|
| |
| |
細胞通路功能狀態的測定方法
|
| |
15/179,119
|
| |
美國待決
|
| |
12/12/2013
|
| |
2034
|
| |
| |
細胞信號分析診斷癌症患者的方法
|
| |
15/533,897美元
|
| |
美國、澳大利亞、加拿大、中國、歐洲、日本、韓國和新西蘭待定
|
| |
12/12/2014
|
| |
2035
|
| |
| |
建立病人細胞微環境的方法
|
| |
pct/US 2016/057923
|
| |
pct待決
|
| |
10/20/2015
|
| |
2036
|
| |
| |
細胞信號分析治療癌症患者的方法
|
| |
62/473,936美元
|
| |
美國待決
|
| |
3/20/2017
|
| |
2038
|
| |
姓名
|
| |
年齡
|
| |
標題
|
|
布萊恩·蘇利文 | | |
55
|
| | 董事會主席兼首席執行官 | |
蘭斯·萊恩 | | |
55
|
| | 首席科學官、副總統、祕書和主任 | |
薇琪·哈尼 | | |
51
|
| | 首席財務官 | |
莫琳·克羅寧 | | |
64
|
| | 導演(1) | |
戴維·戴爾維 | | |
58
|
| | 導演(1) | |
理查德·尼貢 | | |
69
|
| | 導演(1) | |
姓名和職位
|
| |
年
|
| |
工資
($) |
| |
共計
($) |
| |||||||||
布萊恩·蘇利文
首席執行官兼主任 財務主任 |
| | | | 2016 | | | | | $ | 214,077(1) | | | | | $ | 214,077 | | |
| | | 2015 | | | | | $ | 205,077(1) | | | | | $ | 205,077 | | | ||
蘭斯·萊恩
首席科學幹事 |
| | | | 2016 | | | | | | 214,077 | | | | | $ | 214,077 | | |
| | | 2015 | | | | | | 205,077 | | | | | $ | 205,077 | | | ||
薇琪·哈尼
首席財務官 |
| | | | 2016 | | | | | | —(2) | | | | | | —(2) | | |
| | | 2015 | | | | | | —(2) | | | | | | —(2) | | |
| | |
股份
有權受益者 |
| |
佔普通股的百分比
有權受益者 |
| ||||||||||||
實益擁有人的姓名或名稱
|
| |
在提供之前(1)
|
| |
提供後(2)
|
| ||||||||||||
5%股東
|
| |
|
| |
|
| |
|
| |||||||||
環球資源集團(3) | | | | | 680,556 | | | | | | 9.3% | | | | | | 7.0% | | |
董事及指名行政主任 | | | | | | | | | | | | | | | | | | | |
布萊恩·蘇利文(4) | | | | | 2,777,274 | | | | | | 37.8% | | | | | | 28.5% | | |
蘭斯·萊恩(4) | | | | | 1,266,125 | | | | | | 17.3% | | | | | | 13.0% | | |
薇琪·哈尼 | | | | | — | | | | | | — | | | | | | — | | |
莫琳·克羅寧 | | | | | — | | | | | | — | | | | | | — | | |
戴維·戴爾維(5) | | | | | 250,000 | | | | | | 3.4% | | | | | | 2.6% | | |
理查德·尼貢(4) (6)
|
| | | | 97,699 | | | | | | 1.3% | | | | | | 1.0% | | |
所有董事和執行幹事作為一個小組(6人)(4)
|
| | | | 4,391,098 | | | | | | 59.5% | | | | | | 44.9% | | |
承銷商
|
| |
股份數目
|
| |||
克雷格-Hallum資本集團有限責任公司 | | | | | 2,400,000 | | |
共計
|
| | | | 2,400,000 | | |
|
| | |
每股
|
| |
共計
過度- 分配 |
| |
共計
過度- 分配 |
| |||||||||
承銷折扣由我方支付 | | | | $ | 0.665 | | | | | $ | 1,596,000 | | | | | $ | 1,835,400 | | |
項目
|
| |
頁
|
| |||
獨立註冊會計師事務所報告 | | | | | F-2 | | |
截至#date0#12月31日及2015年度12月31日的資產負債表 | | | | | F-3 | | |
截至12月31日、2016和12月31日的年度業務報表,
2015 |
| | | | F-4 | | |
截至#date0#12月31日及2015年月日股東權益變動報表
|
| | | | F-5 | | |
截至12月31日、2016和12月31日的現金流量表,
2015 |
| | | | F-6 | | |
財務報表附註 | | |
F-7-F-14
|
| |||
截至6月30日,2017和6月30日,2016的三個月和六個月:
|
| ||||||
項目 | | |
頁
|
| |||
截至2017(未經審核)及2016年月31的資產負債表 | | | | | F-15 | | |
截至6月30日、2017和6月30日2016(未經審計)的三個月和六個月的業務報表
|
| | | | F-16 | | |
截至#date0#6月30日和2016(未經審計)的6個月現金流量表
|
| | | | F-17 | | |
財務報表附註 | | |
F-18-F-26
|
|
| | |
2016
|
| |
2015
|
| ||||||
資產 | | | | | | | | | | | | | |
流動資產: | | | | | | | | | | | | | |
現金和現金等價物 | | | | $ | 5,856,348 | | | | | $ | 5,067,240 | | |
限制現金 | | | | | 50,000 | | | | | | 50,000 | | |
存款 | | | | | 5,717 | | | | | | 5,717 | | |
流動資產總額
|
| | | | 5,912,065 | | | | | | 5,122,957 | | |
財產和設備,淨額 | | | | | 144,912 | | | | | | 177,068 | | |
總資產
|
| | | $ | 6,056,977 | | | | | $ | 5,300,025 | | |
負債與股東權益 | | | | | | | | | | | | | |
流動負債: | | | | | | | | | | | | | |
應付帳款 | | | | $ | 331,534 | | | | | $ | 261,755 | | |
應計費用 | | | | | 113,825 | | | | | | 21,849 | | |
流動負債總額
|
| | | | 445,359 | | | | | | 283,604 | | |
負債總額
|
| | | | 445,359 | | | | | | 283,604 | | |
承付款和意外開支 | | | | | | | | | | | | | |
股東權益: | | | | | | | | | | | | | |
普通股,45,000,000股,6,440,105股和5,891,147股
截至2016及12月31日為止已發行及發行的股份 分別為2015年月31,票面價值0.001美元。 |
| | | | 6,440 | | | | | | 5,891 | | |
額外已付資本 | | | | | 13,936,579 | | | | | | 10,031,523 | | |
累積赤字 | | | | | (8,331,401) | | | | | | (5,020,993) | | |
股東權益合計
|
| | | | 5,611,618 | | | | | | 5,016,421 | | |
負債總額和股東權益
|
| | | $ | 6,056,977 | | | | | $ | 5,300,025 | | |
|
| | |
2016
|
| |
2015
|
| ||||||
業務費用: | | | | | | | | | | | | | |
研發 | | | | $ | 3,064,762 | | | | | $ | 2,011,719 | | |
一般和行政 | | | | | 263,664 | | | | | | 250,091 | | |
業務費用共計 | | | | | 3,328,426 | | | | | | 2,261,810 | | |
業務損失 | | | | | (3,328,426) | | | | | | (2,261,810) | | |
利息收入 | | | | | 18,018 | | | | | | 268 | | |
淨損失 | | | | $ | (3,310,408) | | | | | $ | (2,261,542) | | |
每股淨虧損,基本損失和稀釋損失 | | | | $ | (0.52) | | | | | $ | (0.39) | | |
加權平均普通股流通股、基礎股和稀釋股 | | | | | 6,313,089 | | | | | | 5,843,317 | | |
| | |
普通股
|
| |
額外
已付 資本 |
| |
成員説明
應收款項 |
| |
累積
赤字 |
| |
共計
股東‘ 權益 |
| |||||||||||||||||||||
| | |
股份
|
| |
票面金額
|
| ||||||||||||||||||||||||||||||
2014年月31結餘
|
| | | | 5,325,218 | | | | | $ | 5,325 | | | | | $ | 6,173,188 | | | | | $ | (1,000,000) | | | | | $ | (2,759,451) | | | | | $ | 2,419,062 | | |
發行普通股,淨額 | | | | | 565,929 | | | | | | 566 | | | | | | 3,801,828 | | | | | | — | | | | | | — | | | | | | 3,802,394 | | |
股票補償 | | | | | — | | | | | | — | | | | | | 56,507 | | | | | | — | | | | | | — | | | | | | 56,507 | | |
為購買的股份支付會員票據所得收益
|
| | | | — | | | | | | — | | | | | | — | | | | | | 1,000,000 | | | | | | — | | | | | | 1,000,000 | | |
淨損失 | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (2,261,542) | | | | | | (2,261,542) | | |
2015年月31結餘
|
| | | | 5,891,147 | | | | | | 5,891 | | | | | | 10,031,523 | | | | | | — | | | | | | (5,020,993) | | | | | | 5,016,421 | | |
發行普通股,淨額 | | | | | 548,958 | | | | | | 549 | | | | | | 3,717,750 | | | | | | — | | | | | | — | | | | | | 3,718,299 | | |
股票補償 | | | | | — | | | | | | — | | | | | | 187,306 | | | | | | — | | | | | | — | | | | | | 187,306 | | |
淨損失 | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,310,408) | | | | | | (3,310,408) | | |
2016年月31結餘
|
| | | | 6,440,105 | | | | | $ | 6,440 | | | | | $ | 13,936,579 | | | | | $ | — | | | | | $ | (8,331,401) | | | | | $ | 5,611,618 | | |
|
| | |
2016
|
| |
2015
|
| ||||||
業務活動現金流量: | | | | | | | | | | | | | |
淨損失
|
| | | $ | (3,310,408) | | | | | $ | (2,261,542) | | |
調整數,將淨虧損與業務所用現金淨額對賬:
|
| | | | | | | | | | | | |
折舊
|
| | | | 73,059 | | | | | | 58,376 | | |
股票補償
|
| | | | 187,306 | | | | | | 56,507 | | |
經營資產和負債的變化:
|
| | | ||||||||||
應付帳款
|
| | | | 69,779 | | | | | | 157,469 | | |
應計費用
|
| | | | 91,976 | | | | | | 10,410 | | |
業務活動使用的現金淨額 | | | | | (2,888,288) | | | | | | (1,978,780) | | |
投資活動的現金流量: | | | | ||||||||||
購置財產和設備 | | | | | (40,903) | | | | | | (78,982) | | |
投資活動使用的現金淨額: | | | | | (40,903) | | | | | | (78,982) | | |
出售普通股的收益,扣除發行成本 | | | | | 3,718,299 | | | | | | 3,802,394 | | |
2014年度應收成員票據權益收益 | | | | | — | | | | | | 1,000,000 | | |
籌資活動提供的現金淨額 | | | | | 3,718,299 | | | | | | 4,802,394 | | |
現金淨增額 | | | | | 789,108 | | | | | | 2,744,632 | | |
年初現金及現金等價物 | | | | | 5,067,240 | | | | | | 2,322,608 | | |
年底現金及現金等價物 | | | | $ | 5,856,348 | | | | | $ | 5,067,240 | | |
|
資產描述
|
| |
估計壽命
|
| |||
傢俱和設備 | | | | | 4 | | |
租賃改良 | | | | | 2-3 | | |
| | |
2016
|
| |
2015
|
| ||||||
租賃改良 | | | | $ | 22,307 | | | | | $ | 22,307 | | |
傢俱和設備 | | | | | 278,020 | | | | | | 237,117 | | |
| | | | | 300,327 | | | | | | 259,424 | | |
減:累計折舊 | | | | | (155,415) | | | | | | (82,356) | | |
合計
|
| | | $ | 144,912 | | | | | $ | 177,068 | | |
|
| | |
經營租賃
|
| |||
2017 | | | | $ | 51,445 | | |
2018 | | | | $ | 21,982 | | |
| | |
2016
|
| |
2015
|
|
無風險利率 | | |
2.00%
|
| |
1.98%
|
|
預期波動率 | | |
75.0%
|
| |
72.0%
|
|
預期壽命(年份) | | |
6.25至10時
|
| |
6.25至10時
|
|
預期股利收益率 | | |
0%
|
| |
0%
|
|
| | |
2016
|
| |
2015
|
| ||||||||||||||||||
| | |
股份
|
| |
加權
平均 運動 價格 |
| |
股份
|
| |
加權
平均 運動 價格 |
| ||||||||||||
年初未完成的備選方案 | | | | | 114,525 | | | | | $ | 3.07 | | | | | | 62,500 | | | | | $ | 2.59 | | |
獲批
|
| | | | 190,063 | | | | | $ | 7.60 | | | | | | 52,025 | | | | | $ | 3.64 | | |
行使
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | |
過期
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | |
被沒收
|
| | | | (2,500) | | | | | $ | 3.60 | | | | | | — | | | | | $ | — | | |
年底結餘
|
| | | | 302,088 | | | | | $ | 5.91 | | | | | | 114,525 | | | | | $ | 3.07 | | |
可於十二月三十一日行使的期權: | | | | | 71,463 | | | | | $ | 2.91 | | | | | | 31,317 | | | | | $ | 2.47 | | |
下列期間授予期權的加權平均授予日期公允價值:
|
| | | | | | | | | $ | 5.22 | | | | | | | | | | | $ | 2.47 | | |
|
備選方案---傑出
|
| |
可行使的期權
|
| |||||||||||||||||||||||||||||||||
|
備選方案
突出 |
| |
加權
平均 剩餘 契約性 生命 |
| |
加權
平均 運動 價格 |
| |
骨料
內稟 價值 |
| |
備選方案
可鍛鍊 |
| |
加權
平均 運動 價格 |
| |
骨料
內稟 價值 |
| ||||||||||||||||||
| 302,088 | | | | | 8.80 | | | | | $ | 5.91 | | | | | $ | 497,862 | | | | | | 71,463 | | | | | $ | 2.91 | | | | | $ | 332,692 | | |
| 2017 | | | | $ | 364,753 | | |
| 2018 | | | | | 253,316 | | |
| 2019 | | | | | 225,875 | | |
| 2020 | | | | | 110,833 | | |
| 待確認的估計賠償費用總額 | | | |
$
|
954,777
|
| |
|
| | |
六月三十日,
2017 |
| |
十二月三十一日,
2016 |
| ||||||
| | |
(未經審計)
|
| | ||||||||
資產
|
| | | | | | | | | | | | |
流動資產: | | | | ||||||||||
現金和現金等價物 | | | | $ | 10,908,068 | | | | | $ | 5,856,348 | | |
限制現金 | | | | | 50,000 | | | | | | 50,000 | | |
存款 | | | | | 5,717 | | | | | | 5,717 | | |
遞延交易費用 | | | | | 301,730 | | | | | | — | | |
預付資產 | | | | | 156,120 | | | | | | — | | |
流動資產總額
|
| | | | 11,421,635 | | | | | | 5,912,065 | | |
財產和設備,淨額 | | | | | 265,315 | | | | | | 144,912 | | |
總資產
|
| | | $ | 11,686,950 | | | | | $ | 6,056,977 | | |
負債和股東權益: | | | | | | | | | | | | | |
流動負債: | | | | | | | | | | | | | |
應付帳款 | | | | $ | 519,867 | | | | | $ | 331,534 | | |
應計費用 | | | | | 257,087 | | | | | | 113,825 | | |
流動負債總額
|
| | | | 776,954 | | | | | | 445,359 | | |
長期負債 | | | | | 6,575,413 | | | | | | — | | |
承付款和意外開支 | | | | | | | | | | | | | |
股東權益: | | | | | | | | | | | | | |
普通股,截至2017和2016年6月30日和2016年12月31日,獲授權發行股票45,000,000股,發行和發行股票6,440,105股,票面價值0.001美元
|
| | | | 6,440 | | | | | | 6,440 | | |
額外已付資本 | | | | | 15,423,110 | | | | | | 13,936,579 | | |
累積赤字 | | | | | (11,094,967) | | | | | | (8,331,401) | | |
股東權益合計
|
| | | | 4,334,583 | | | | | | 5,611,618 | | |
負債總額和股東權益
|
| | | $ | 11,686,950 | | | | | $ | 6,056,977 | | |
|
| | |
三個月的6月30日,
|
| |
六個月的6月30日,
|
| ||||||||||||||||||
| | |
2017
|
| |
2016
|
| |
2017
|
| |
2016
|
| ||||||||||||
業務費用: | | | | | | | | | | | | | | | | | | | | | | | | | |
研發 | | | | $ | 1,303,886 | | | | | $ | 751,505 | | | | | $ | 2,212,629 | | | | | $ | 1,412,056 | | |
一般和行政 | | | | | 301,820 | | | | | | 72,339 | | | | | | 386,963 | | | | | | 131,417 | | |
業務費用共計 | | | | | 1,605,706 | | | | | | 823,844 | | | | | | 2,599,592 | | | | | | 1,543,473 | | |
業務損失 | | | | | (1,605,706) | | | | | | (823,844) | | | | | | (2,599,592) | | | | | | (1,543,473) | | |
其他收入(費用) | | | | | | ||||||||||||||||||||
利息費用 | | | | | (186,659) | | | | | | — | | | | | | (186,686) | | | | | | — | | |
利息收入 | | | | | 16,150 | | | | | | 3,859 | | | | | | 22,712 | | | | | | 4,019 | | |
其他收入(費用),淨額 | | | | | (170,509) | | | | | | 3,859 | | | | | | (163,974) | | | | | | 4,019 | | |
淨損失 | | | | $ | (1,776,215) | | | | | $ | (819,985) | | | | | $ | (2,763,566) | | | | | $ | (1,539,454) | | |
每股淨虧損,基本損失和稀釋損失 | | | | $ | (0.28) | | | | | $ | (0.13) | | | | | $ | (0.43) | | | | | $ | (0.25) | | |
加權平均普通股流通股、基礎股和稀釋股
|
| | | | 6,440,105 | | | | | | 6,344,251 | | | | | | 6,440,105 | | | | | | 6,181,660 | | |
| | |
2017
|
| |
2016
|
| ||||||
業務活動現金流量: | | | | | | | | | | | | | |
淨損失
|
| | | $ | (2,763,566) | | | | | $ | (1,539,454) | | |
調整數,將淨虧損與業務所用現金淨額對賬:
|
| | | | | | | | | | | | |
折舊
|
| | | | 45,449 | | | | | | 35,484 | | |
股票補償
|
| | | | 422,816 | | | | | | 36,301 | | |
非現金利息費用
|
| | | | 186,759 | | | | | | — | | |
經營資產和負債的變化:
|
| | | | | | | | | | | | |
預付資產
|
| | | | (156,120) | | | | | | — | | |
應付帳款
|
| | | | (34,771) | | | | | | 46,038 | | |
應計費用
|
| | | | 89,700 | | | | | | 18,738 | | |
業務活動使用的現金淨額 | | | | | (2,209,733) | | | | | | (1,402,893) | | |
投資活動的現金流量: | | | | | | | | | | | | | |
購置財產和設備 | | | | | (165,851) | | | | | | (29,863) | | |
投資活動使用的現金淨額: | | | | | (165,851) | | | | | | (29,863) | | |
來自籌資活動的現金流量: | | | | | | | | | | | | | |
出售普通股的收益,扣除發行成本 | | | | | — | | | | | | 3,718,300 | | |
出售可兑換本票所得收益 | | | | | 7,493,330 | | | | | | — | | |
償還債務發行費用 | | | | | (40,961) | | | | | | — | | |
遞延交易費用 | | | | | (25,065) | | | | | | — | | |
籌資活動提供的現金淨額 | | | | | 7,427,304 | | | | | | 3,718,300 | | |
現金淨增額 | | | | | 5,051,720 | | | | | | 2,285,544 | | |
期初現金及現金等價物 | | | | | 5,856,348 | | | | | | 5,067,240 | | |
期末現金及現金等價物 | | | | $ | 10,908,068 | | | | | $ | 7,352,783 | | |
非現金融資活動: | | | | ||||||||||
與出售可轉換期票有關的債務發行費用 | | | | $ | 844,170 | | | | | $ | — | | |
與投資者及代理人認股權證有關的債務折扣(注7) | | | | | 1,063,715 | | | | | | — | | |
應付帳款和應計費用中包括的遞延交易費用
|
| | | | 276,666 | | | | | | — | | |
資產描述
|
| |
估計值
生命 |
| |||
傢俱和設備 | | | | | 4 | | |
租賃改良 | | | | | 2-3 | | |
| | |
六月三十日,
2017 |
| |
十二月三十一日,
2016 |
| ||||||
| | |
(未經審計)
|
| | ||||||||
租賃改良 | | | | $ | 22,307 | | | | | $ | 22,307 | | |
傢俱和設備 | | | | | 443,871 | | | | | | 278,020 | | |
| | | | | 466,178 | | | | | | 300,327 | | |
減:累計折舊 | | | | | (200,863) | | | | | | (155,415) | | |
合計
|
| | | $ | 265,315 | | | | | $ | 144,912 | | |
|
| | |
經營租賃
|
| |||
剩餘的2017 | | | | $ | 26,379 | | |
2018 | | | | $ | 21,982 | | |
| | |
2017
|
| |
2016
|
|
無風險利率 | | |
2.00%
|
| |
2.00%
|
|
預期波動率 | | |
75.0%
|
| |
72.0%
|
|
預期壽命(年份) | | |
6.25至10時
|
| |
6.25至10時
|
|
預期股利收益率 | | |
0%
|
| |
0%
|
|
| | |
2017
|
| |
2016
|
| ||||||||||||||||||
| | |
股份
|
| |
加權
平均 運動 價格 |
| |
股份
|
| |
加權
平均 運動 價格 |
| ||||||||||||
年初未完成的備選方案 | | | | | 302,088 | | | | | $ | 5.91 | | | | | | 114,525 | | | | | $ | 3.07 | | |
獲批
|
| | | | 148,150 | | | | | $ | 8.38 | | | | | | 169,750 | | | | | $ | 7.60 | | |
被沒收
|
| | | | (7,553) | | | | | $ | 3.60 | | | | | | — | | | | | $ | — | | |
6月30日餘額
|
| | | | 442,685 | | | | | $ | 6.78 | | | | | | 284,275 | | | | | $ | 5.27 | | |
可於六月三十日行使的期權: | | | | | 166,119 | | | | | $ | 5.46 | | | | | | 52,192 | | | | | $ | 2.78 | | |
本期間授予的期權的加權平均授予日期公允價值:
|
| | | | | | | | | $ | 5.29 | | | | | | | | | | | $ | 5.22 | | |
|
備選方案---傑出
|
| |
可行使的期權
|
| |||||||||||||||||||||||||||||||||
|
備選方案
突出 |
| |
加權
平均 剩餘 契約性 生命 |
| |
加權
平均 運動 價格 |
| |
骨料
內稟 價值 |
| |
備選方案
可鍛鍊 |
| |
加權
平均 運動 價格 |
| |
骨料
內稟 價值 |
| ||||||||||||||||||
| 442,685 | | | | | 8.86 | | | | | $ | 6.78 | | | | | $ | 475,005 | | | | | | 166,119 | | | | | $ | 5.46 | | | | | $ | 382,906 | | |
| 剩餘的2017 | | | | $ | 259,655 | | |
| 2018 | | | | | 395,865 | | |
| 2019 | | | | | 354,499 | | |
| 2020 | | | | | 239,456 | | |
| 2021 | | | | | 61,081 | | |
|
待確認的估計賠償費用總額
|
| | |
$
|
1,309,556
|
| |
|